Skip to main content

Filters

Evidence

Handbooks/Manuals

News

Can inositol (a supplement that helps control blood sugar and hormones) help women with polycystic ovary syndrome (a common hormone condition that affects fertility) have a baby?

Key messages

  • In general, we are unsure whether myo-inositol (a supplement that helps control blood sugar and hormones) can help women with polycystic ovary syndrome (a common hormone condition that affects fertility) have a baby. We are also unsure of its effect on unwanted events like losing a pregnancy.

  • In women having in vitro fertilisation (where eggs are collected from the ovaries and fertilised with sperm in a laboratory), myo-inositol, compared to routine treatment (folic acid), may increase slightly the chances of getting pregnant (confirmed by ultrasound), but not necessarily the chances of having a baby.

  • We need better studies to find out whether different types of inositol (myo-inositol and D-chiro-inositol) can help women with PCOS get pregnant safely. Studies should cover different stages of fertility treatment and also include women trying to get pregnant naturally.

What is polycystic ovary syndrome?

Polycystic ovary syndrome (PCOS), which was renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026, is a common hormone condition that affects about one in eight women worldwide. It can cause irregular periods, extra hair growth or hair loss, weight gain, difficulty getting pregnant, and mood problems. Although there is no cure for PCOS, treatments and lifestyle changes can help with symptoms.

How could inositol help women with polycystic ovary syndrome get pregnant and have a baby?

Women with PCOS may not ovulate regularly due to a hormone imbalance. Inositol is a natural substance found in foods like fruit, nuts, and beans, and the body also makes it from sugar. It is widely available as a dietary supplement, and early research suggests it may help the body use insulin better, which could improve hormone balance and help the ovary develop eggs.

What did we want to find out?

We wanted to see if taking inositol could help women with PCOS who are having trouble getting pregnant. Specifically, we wanted to know whether inositol:

  • improves women's chances of:

    • having a baby; or

    • getting pregnant (confirmed by ultrasound).

  • affects the risk of women:

    • losing a pregnancy;

    • having a multiple pregnancy (carrying two or more babies);

    • developing ovarian hyperstimulation syndrome (when the ovaries produce too many eggs at once); or

    • developing gestational diabetes (high blood sugar while pregnant).

What did we do?

We searched for studies that compared inositol with placebo (dummy treatment) or no treatment, or that compared different types of inositol, in women with PCOS who were trying to get pregnant, with or without fertility treatment. Fertility treatment includes:

  • ovulation induction, where medicines help the ovaries release eggs (ovulate);

  • intrauterine insemination, where prepared sperm is placed directly into the womb around the time of ovulation; and

  • in vitro fertilisation (IVF), where eggs are collected from the ovaries and fertilised with sperm in a laboratory.

What did we find?

We found 21 studies that included 1634 women with PCOS. Studies took place in Iran, India, Italy, Albania, Germany, and Vietnam. All the women were receiving routine pre-pregnancy care. Most studies looked at myo-inositol, which is a form of inositol. A few studies looked at another form called D-chiro-inositol, but they didn't report results we could use.

Main results

Our main results are based on studies that used an appropriate random method to assign women to treatment groups.

In women with PCOS undergoing ovulation induction or intrauterine insemination (1 study, 120 women), we are unsure about the effects of myo-inositol, compared to no treatment, on:

  • having a baby;

  • getting pregnant;

  • losing a pregnancy;

  • having a multiple pregnancy;

  • developing ovarian hyperstimulation syndrome; or

  • developing gestational diabetes.

In women with PCOS undergoing in vitro fertilisation, we are unsure about the effects of myo-inositol, compared to no treatment, on:

  • having a baby (2 studies, 84 women);

  • losing a pregnancy (2 studies, 84 women); or

  • having a multiple pregnancy (1 study, 34 women).

In these women, myo-inositol may slightly improve women's chances of getting pregnant (3 studies, 164 women). Compared to an expected pregnancy rate of 15% with no treatment, the chance of getting pregnant using myo-inositol may range from 15% to 46%.

In women with PCOS undergoing in vitro fertilisation (1 study, 102 women), we are unsure about the effect of myo-inositol, compared to metformin (a pill that helps to lower blood sugar, commonly used for PCOS), on

  • having a baby;

  • getting pregnant;

  • losing a pregnancy; or

  • developing ovarian hyperstimulation syndrome.

What are the limitations of evidence?

We are not confident in the evidence, because some studies included few women, reported few events, or had weaknesses in their design. Some studies did not report the outcomes that matter most to women, such as having baby, losing a pregnancy, or unwanted effects of treatment.

How up‐to‐date is this review?

This review updates our previous review published in 2018. The evidence is current to 10 November 2025.

Background

Subfertile women are highly motivated to try different adjunctive therapies to have a baby, and the widespread perception is that dietary supplements such as myo-inositol (MI) and D-chiro-insoitol (DCI) are associated with only benefit, and not with harm. Many fertility clinicians currently prescribe MI for subfertile women with polycystic ovary syndrome (PCOS) as pre-treatment to in vitro fertilisation (IVF) or for ovulation induction; however no high-quality evidence is available to support this practice. This review assessed the evidence for the effectiveness of inositol in subfertile women with a diagnosis of PCOS.

Objectives

To evaluate the benefits and harms of inositol oral supplementation for reproductive outcomes among women with polycystic ovary syndrome experiencing infertility.

Search strategy

We searched CENTRAL (which includes trial registries), the Cochrane Gynaecology and Fertility Group Specialised Register, MEDLINE, Embase, PsycINFO, AMED, and Epistemonikos to 10 November 2025. We also checked reference lists and contacted experts in the field for any additional trials.

Selection criteria

We included randomised controlled trials (RCTs) that compared any type, dose, or combination of oral inositol versus placebo, no treatment/standard treatment, or treatment with another antioxidant, or with a fertility agent, or with another type of inositol, among subfertile women with PCOS.

Data collection and analysis

Two review authors independently selected eligible studies, extracted data, and assessed risk of bias. The primary outcomes were live birth and adverse effects; secondary outcomes included clinical pregnancy rates and ovulation rates. We pooled studies using a fixed-effect model, and we calculated odds ratios (ORs) with 95% confidence intervals (CIs). We assessed the overall quality of the evidence by applying GRADE criteria.

Main results

We included 13 trials involving 1472 subfertile women with PCOS who were receiving myo-inositol as pre-treatment to IVF (11 trials), or during ovulation induction (two trials). These studies compared MI versus placebo, no treatment/standard, melatonin, metformin, clomiphene citrate, or DCI. The evidence was of 'low' to 'very low' quality. The main limitations were serious risk of bias due to poor reporting of methods, inconsistency, and lack of reporting of clinically relevant outcomes such as live birth and adverse events.

We are uncertain whether MI improves live birth rates when compared to standard treatment among women undergoing IVF (OR 2.42, 95% CI 0.75 to 7.83; P = 0.14; 2 RCTs; 84 women; I² = 0%). Very low-quality evidence suggests that for subfertile women with PCOS undergoing pre-treatment to IVF who have an expected live birth rate of 12%, the rate among women using MI would be between 9% and 51%.

We are uncertain whether MI may be associated with a decrease in miscarriage rate when compared to standard treatment (OR 0.40, 95% CI 0.19 to 0.86; P = 0.02; 4 RCTs; 535 women; I² = 66%; very low-quality evidence). This suggests that among subfertile women with PCOS with an expected miscarriage rate of 9% who are undergoing pre-treatment to IVF, the rate among women using MI would be between 2% and 8%; however this meta-analysis is based primarily on one study, which reported an unusually high miscarriage rate in the control group, and this has resulted in very high heterogeneity. When we removed this trial from the sensitivity analysis, we no longer saw the effect, and we noted no conclusive differences between MI and standard treatment.

Low-quality evidence suggests that MI may be associated with little or no difference in multiple pregnancy rates when compared with standard treatment (OR 1.04, 95% CI 0.63 to 1.71; P = 0.89; 2 RCTs; 425 women). This suggests that among subfertile women with PCOS who are undergoing pre-treatment to IVF, with an expected multiple pregnancy rate of 18%, the rate among women using inositol would be between 12% and 27%.

We are uncertain whether MI may be associated with an increased clinical pregnancy rate when compared to standard treatment (OR 1.27, 95% CI 0.87 to 1.85; P = 0.22; 4 RCTs; 535 women; I² = 0%; very low-quality evidence). This suggests that among subfertile women with PCOS who are undergoing pre-treatment to IVF, with an expected clinical pregnancy rate of 26%, the rate among women using MI would be between 24% and 40%. Ovulation rates were not reported for this comparison.

Other comparisons included only one trial in each, so for the comparisons MI versus antioxidant, MI versus an insulin-sensitising agent, MI versus an ovulation induction agent, and MI versus another DCI, meta-analysis was not possible.

No pooled evidence was available for women with PCOS undergoing ovulation induction, as only single trials performed comparison of the insulin-sensitising agent and the ovulation induction agent.

Authors' conclusions

In light of the very low-certainty evidence available from one study, we are unsure whether myo-inositol, compared with no treatment, has an effect on live birth, miscarriage, multiple pregnancy, OHSS, clinical pregnancy, or gestational diabetes in women with PCOS and infertility undergoing ovulation induction/intrauterine insemination.

In studies comparing myo-inositol with no treatment in women undergoing IVF, the certainty of the evidence was very low for live birth, miscarriage, and multiple pregnancy. Low-certainty evidence from three of these studies indicated there may be a slight increase in clinical pregnancy rates for women taking myo-inositol compared with those receiving no treatment.

In light of the very low-certainty evidence available from one study, we are unsure whether myo-inositol, compared with metformin, has an effect on live birth, miscarriage, OHSS, or clinical pregnancy in women undergoing IVF.

Funding

This Cochrane review had no dedicated funding.

Registration

Protocol (2016) available at https://doi.org/10.1002/14651858.CD012378.

Previous review (2018) available at https://doi.org/10.1002/14651858.CD012378.pub2.

Citation
Vercoe MA, Rodenburg C, Mackenzie-Proctor R, Jordan VMB, Hodgson R, Farquhar C, Showell MG, Supported by the Cochrane Gynaecology and Fertility Review Group. Inositol for infertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2026, Issue 11. Art. No.: CD012378. DOI: 10.1002/14651858.CD012378.pub3.

Our use of cookies

We use necessary cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. We won't set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences. You can always change your cookie preferences at any time by clicking on the 'Cookies settings' link in the footer of every page.
For more detailed information about the cookies we use, see our Cookies page.

Accept all
Configure